iPS Cells & Regenerative Medicine Weekly Report July 5, 2026

FDA Manufacturing PreCheck Pilot Program Selects 7 Companies Including Cellares to Streamline and Expedite Cell Therapy Manufacturing Processes

Strategic Capital Influx in Gene Therapy: Pfizer Invests in CRISPR Biotech, AstraZeneca Strengthens China Cell Therapy Capabilities

Biopharma M&A Accelerates in H1 2026: Eli Lilly Leads with Over $25 Billion Spend as Big Pharma Bolsters Pipelines

Capricor Therapeutics to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Conference

FDA Issues Over Six Warning Letters for Unapproved Exosome Therapies in US, Citing Illegal Sales and Unsubstantiated Claims (2024-2026)

Australian iCamuno Biotherapeutics Launches Clinical Trial for Parkinson’s with ‘Hypoimmune Neural Cell Therapy’ Avoiding Immunosuppression

FDA Approves Orca-T, First Regulatory T-Cell Therapy to Improve Chronic GVHD-Free Survival in Blood Cancer Patients Undergoing Allogeneic HSCT

Fate Therapeutics to Present iPSC-Derived Cell Immunotherapy Pipeline Progress at Investor Conferences